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Abstract 
 
A new series of simplified azasordarin analogs was synthesized using as key steps a Diels–Alder reaction to 
generate a highly substituted bicyclo[2.2.1]heptane core, followed by a subsequent nitrile alkylation. Several 
additional strategies were investigated for the generation of the key tertiary nitrile or aldehyde thought to be 
required for inhibition at the fungal protein eukaryotic elongation factor 2. This new series also features a 
morpholino glycone previously reported in semisynthetic sordarin derivatives with broad spectrum antifungal 
activity. Despite a lack of activity against Candida albicans for these early de novo analogs, the synthetic route 
reported here permits more comprehensive modifications of the bicyclic core and structure–activity relationship 
studies that were not heretofore possible. 
Introduction 
The development of resistance to the relatively small number of antifungal agents in clinical use for invasive 
fungal infections is now of great concern. It is estimated that more than 2 million people die annually of invasive 
fungal infections, which can have mortality rates of >50%.(1) Additionally, fungi are estimated to destroy 
approximately 20% of crops worldwide. With increasing resistance observed for both clinical and agricultural 
antifungals, the identification of new classes of antifungals is an urgent matter.(2−4) In 1965, Sigg and Stoll from 
Sandoz AG submitted a patent application first describing the natural product sordarin as an antibacterial and 
antifungal agent.(5) First isolated from the fungus Sordaria araneosa,(6) sordarin has a unique tetracyclic 
diterpene scaffold, with a [2.2.1]heptene at its core with adjacent aldehyde and acid groups (1, Figure 1). 
Attached to the core is an unusual carbohydrate glycone, which can be replaced with a multitude of substituents 
via semisynthesis, leading to derivatives such as 2 (GW 471558)(7) and 3.(8) 
 
 
 
Figure 1. Sordarin and two representative azasordarin derivatives (top); known sordarin structure–activity 
relationship (SAR) and our plan for simplified analogs via scaffold simplification (bottom). 
 
Importantly, the antifungal target of sordarin was later deduced by groups at Merck and Glaxo to be the 
ribosomal protein eukaryotic elongation factor 2 (eEF2),(9,10) a necessary component of protein synthesis 
which is a target presently unaddressed by current clinical antifungals. The high potency against fluconazole-
resistant fungal strains and selectivity for sordarin derivatives over human eEF2 provided additional impetus for 
numerous pharmaceutical companies to pursue sordarin derivatives as antifungal agents. The complexity of 
sordarin as a synthetic target necessitated the near-exclusive pursuit of semisynthetic derivatives, since sordarin 
can be produced on large scales via fermentation,(11) and the natural glycone easily hydrolyzed and replaced 
with alternatives that imbue the derivatives with improved properties. Despite these efforts, to our knowledge, 
no fungal eEF2 inhibitors have reached clinical stages. This manuscript describes our efforts thus far to 
synthesize novel analogs possessing a simplified bicyclic [2.2.1] scaffold more amenable to systematic 
modifications, which could lead to sordarin analogs with improved properties for clinical use. The strategy of 
identifying natural product pharmacophores and preparing structurally simpler compounds has been 
conceptualized by Wender (Function-Oriented Synthesis)(12) and has a long and successful history in medicinal 
chemistry. Important examples include the discovery of morphine-inspired opioids such as 
fentanyl,(13) synthetic statins such as atorvastatin inspired by the natural HMG-CoA reductase inhibitors 
compactin and lovastatin,(14,15) and the anticancer drug eribulin identified from the simplification of the 
sponge metabolite halichondrin B.(16) We believe that this underutilized approach could be fruitfully applied to 
sordarin. 
 
Design of Analogs 
Semisynthetic replacement of the glycone of sordarin has led to several highly potent and orally active 
azasordarin analogs against Candida albicans such as 2 (Figure 1)(7) as well as a few analogs with a broader 
spectrum of antifungal activity (e.g., 3).(8) One liability that has been identified with certain sordarin derivatives 
is their unsatisfactory metabolic stabilities. Sordarin and its aglycone sordaricin are hydroxylated on the 
cyclopentane (Figure 1, bottom left) by rat and mouse hepatic fractions.(17) We hypothesize that analogs with 
alternative scaffolds, particularly those with substituents at the “western” side that are resistant to cytochrome 
P-450-mediated oxidation, could maintain the pharmacophore for antifungal activity (Figure 1, bottom right) 
and possess improved pharmacokinetic (PK) profiles. Previous SAR studies have suggested that the key part of 
the sordarin pharmacophore is the vicinal aldehyde-carboxylic acid, held within the rigid bicyclic framework in a 
perpendicular orientation which precludes hemiacetal formation.(18) X-ray crystal structures of eEF2 complexed 
with sordarin have clarified the importance of the aldehyde and acid moieties, which form four hydrogen bonds 
with bound waters and two backbone amides of eEF2 (Figure 2).(19,20) It should be noted that several potent 
analogs have been reported where the aldehyde has been replaced with a nitrile.(18) We reasoned that a 
modified bicyclo[2.2.1]heptane core could maintain a similar dihedral angle between these moieties and permit 
the identification of novel analogs with comparable potencies to the natural product and its semisynthetic 
derivatives, but with the potential for improved PK properties. A simplified monocyclic cyclopentane with vicinal 
aldehyde and acid moieties was previously reported by Cuevas to possess only marginal antifungal activity.(17) 
 
 
 
Figure 2. X-ray structure of eEF2-sordarin.(19) 
 
Reasoning that the isopropyl group may not be required for activity, and its introduction would complicate the 
current synthetic routes under consideration, we initially pursued analogs without a substituent at C-6 of the 
bicycle. Alternatively, the crystal structure suggests that a small group at C-5 could be tolerated, which 
complements our current synthetic approach. Therefore, primarily for synthetic expediency, we have initially 
prepared the scaffold present in 4 (Figure 1) possessing an exo-methylene at C-5. 
 
As described in our previous report,(21) we successfully established a synthetic route to simplified [2.2.1] 
bicyclic analogs of sordarin (Scheme 1). This route relied on chromatographic separation of endo/exo Diels–
Alder adduct rac-15 to give endo-15. Subsequent protecting group manipulation followed by Wittig reaction and 
Jones oxidation furnished simplified alkyl sordarin analog 17. However, 17 failed to show antifungal activity 
against several strains of C. albicans at concentrations up to 8 μg/mL. We reasoned that this may be attributed 
to the lack of a complex glycone and/or the lack of a quaternary center at C-2. Therefore, we chose to append to 
our scaffold a morpholine glycone previously reported in sordarin derivatives showing broad and potent 
antifungal activity (3, Figure 1).(8) 
 
 
 
Scheme 1. Synthesis of Our First-Generation Sordarin Analogs(21) 
 
To construct the tertiary chiral center at C-2, we have thus far explored five strategies for the preparation of key 
intermediates 5 that are suitable for the elaboration to the desired analogs 4 (Figure 3). A Diels–Alder approach 
using 1,1-disubstituted alkenes could be the most convergent approach to 5. Reactions using silyloxy 
diene 6 could avert undesired 1,5-hydride or alkyl shifts that are well known for cyclopentadienes(22) but are 
slowed down by electron-rich diene substituents.(23) The silyloxy group is also a versatile handle for subsequent 
transformations, and provides the desired regioselectivity for cycloadditions, with the aldehyde/nitrile and 
carboxylic acid precursors on vicinal carbons in the cycloadducts. The endo/exo diastereoselectivity could also 
be modified by using suitable Lewis acids. The second approach uses as the key step an asymmetric 
organocatalytic Diels–Alder reaction reported by Jørgensen,(24) which could also provide highly 
enantiomerically enriched products via the catalytic enamine intermediate 7. This approach would also have the 
advantage of avoiding the need to preactivate the diene component via silylenol ether formation. The third 
approach also involves a formal [4 + 2] cycloaddition reaction, but one which could proceed via a double Michael 
addition mechanism. In this proposed reaction, enolate 8 could add to the dienophile to generate a second 
enolate, which could subsequently cyclize by adding back to the resulting enone. The fourth strategy, which 
depends on a prior cycloaddition reaction, is to install the nitrile on the endo face of the bicycle by the addition 
of cyanide to an intermediate carbocation 9. The fifth strategy leverages our prior cycloaddition reactions with 
acrylonitrile,(21) but uses a subsequent SNAr or SN2 substitution reaction to introduce the aryl or alkyl 
substituent via the exo face of the bicycle. 
 Figure 3. Proposed strategies for constructing the desired bicyclo[2.2.1]heptane core with quaternary center at 
C-2. PG = protecting group, LG = leaving group. 
 
Results and Discussion 
Diels–Alder with Silyloxy Diene 
Our initial target compounds possess a fluorinated aryl group as R1 (4, Figure 1), which we hypothesize should fit 
into the lipophilic portion of the eEF2 binding pocket occupied by the cyclopentane ring of sordarin. The 
installation of such aryl substituents has proven to be challenging thus far. Our initial attempt used the 2-aryl-
acrolein 18, but instead of the desired adduct 19, the unexpected dihydropyran 20 was obtained (Scheme 2). 
This product could be generated from either a retro-Claisen rearrangement of 19 or an inverse electron 
demand, hetero Diels–Alder reaction. Davies reported that Lewis acid-catalyzed reactions of cyclopentadiene 
and 2-arylacroleins generated mixtures of bicyclo[2.2.1]heptenes and dihydropyrans analogous to 19 and 20, 
with the heptenes able to convert to the dihydropyrans.(25) One notable difference in our case is that the 
dihydropyran was the only product observed. The aldehyde-containing Diels–Alder adduct and its rearranged 
product are expected to be in equilibrium, with the ratio determined in part by the ring strain and extent of 
conjugation of the α-substituent (in this case, a fluorinated arene).(26) Silyl ketal 20 is an unstable species that 
decomposed to racemic aldehyde 21 upon treatment with formic acid in methanol or after storage in the freezer 
(−20 °C) for a month dissolved in dichloromethane (DCM) under neutral conditions. The most straightforward 
way to circumvent the undesired hetero Diels–Alder reaction could be to use the nitrile or ester counterparts 
of 18, but unfortunately these dienophiles failed to give any cycloadducts with 14. 
 
 
 
Scheme 2. Diels–Alder/Retro-Claisen or Hetero Diels–Alder Reaction of Enal 18 
 
To potentially circumvent the lack of Diels–Alder reactivity of acrylates, we turned our attention to the α,β-
unsaturated ester 22 with a more highly activating trifluoromethyl methyl group to decrease the lowest 
unoccupied molecular orbital level of the dienophile. The trifluoromethyl group is also a desirable substituent 
for our medicinal chemistry studies due to its lipophilic but metabolically stable profile. After extensive 
screening of different solvents and Lewis acids, we learned that diene 14 was indeed not compatible with most 
Lewis or Brønsted acids (e.g., trifluoroethanol, Table1, entry 15), as reported by Gleason for a related OTBS-
substituted cyclopentadiene.(23)Lewis acids that were compatible with 14 (Mg(OTf)2, Mg(ClO4)2, and Eu(hfc)3; 
entries 4, 18, and 19) did not give any endo selectivity. The diastereomers were tentatively assigned based on a 
report by Ishihara characterizing endo/exo isomers with the same dienophile.(27) The diastereoselectivity can 
be tilted slightly by using different solvents; the highest exo selectivity was achieved in DCM (Table1, entries 8 
and 9), and the most endo-selective reaction was in hexanes (Table1, entry 11). Due to the low tolerance 
of 14 to Lewis acids, we did not pursue alternative dienophile/Lewis acid combinations to increase the 
proportion of the desired endo cycloadducts, though we anticipate that bulkier substituents than CF3 may favor 
the desired endo cycloadducts. 
 
Table 1. Solvent and Lewis Acid Screening for Diels–Alder Using 22a 
 
entry solvent temp. (°C) Lewis acide endo/exob yieldc 
1 DCM –78 to rt InCl3 N/A decomp. 
2 DCM –78 to rt ZnBr2 N/A decomp. 
3 DCM –78 to rt Yb(OTf)3 N/A decomp. 
4 DCM –78 to rt Mg(OTf)2 0.75 68% 
5 DCM –78 to rt Zn(OTf)2 N/A decomp. 
6 DCM –78 to rt Eu(OTf)3 N/A decomp. 
7 DCM –78 to rt K-10 N/A decomp. 
8 DCM –78 to rt   0.67 83% 
9 DCM rt   0.71d 40%d 
10 THF rt   0.82 85% 
11 hexanes rt   1.04 96% 
12 MeCN rt   0.85 91% 
13 acetone rt   0.8 63% 
14 MeOH rt   0.93 86% 
15 F3CCH2OH rt   N/A decomp. 
16 PhCF3 rt   0.83 100% 
17 EtOAc rt   0.78 74% 
18 MeCN rt Mg(ClO4)2 0.87 98% 
19 CDCl3 rt Eu(hfc)3 0.62 trace 
a Diene was washed with phosphate buffer (pH 7) before using; all experiments were run for 24 h. 
b Diastereomers were assigned based on a previously reported analog,(27) and the ratio was determined with 
19F NMR. 
c NMR yield using pentachloroethane as an internal standard, unless otherwise specified. 
d Isolated yield. 
e 1 equiv except for entry 18 (0.9 equiv) and entry 19 (0.2 equiv). decomp. = diene decomposed to 13. K-10 = 
montmorillonite K-10. Eu(hfc)3 = europium tris[3-(heptafluoropropylhydroxymethylene)-(+)-camphorate]. rt = 
room temperature (22–23 °C). 
 
Asymmetric Organocatalytic Diels–Alder 
To achieve an endo-selective Diels–Alder reaction and avoid the acid sensitivity of diene 14, we examined the 
organocatalytic asymmetric Diels–Alder reaction reported by Jørgensen.(24) The quinidine-derived amine 
catalyst 25 worked smoothly with cyclopentenone (Table2, entry 1), as was reported. However, we were not 
able to extend the scope to include 4-substituted cyclopentenones (entries 2 and 3). When the C-4 position of 
the cyclopentenone is disubstituted, the reaction did not proceed (entry 2), likely because the transition state is 
disrupted by the steric repulsion between the dienamine intermediate and the dienophile. When the C-4 
position is monosubstituted (24c), the enone was consumed, but no cycloaddition products were observed 
(entry 3). 
 
Table 2. Organocatalytic Diels–Alder using Cyclopentenones 24 
 
entry enone T/t result 
1 24a 60 °C, 3 days 100% conversion to 26aa 
2 24b 60 °C, 3 days; 100 °C, 24 h NRa 
3 24c 60 °C, 2 days decomposed 24cb 
a Determined by gas chromatography–mass spectrometry. 
b Determined by 1H NMR. 
 
Double Michael Addition 
Inspired by Yamada’s reports of stereoselective sequential Michael reactions using enolates generated from 3-
alkoxy-cyclopentenones to generate [2.2.1] bicyclic adducts (Scheme 3),(28) we explored an analogous reaction 
starting from our enone 24c and model enone 24b. These were treated with lithium diisopropylamide (LDA) to 
give their corresponding lithium enolates, followed by the addition of an initial Michael acceptor. However, all 
enolates were unreactive in the presence of several Michael acceptors under a number of different conditions 
(Table3). Despite the fact that the cyclopentanone can be smoothly deprotonated, as demonstrated by D2O 
quench (entry 8), use of Michael acceptors with different reactivities ranging from methyl 2-(4-
fluorophenyl)acrylate to acrylonitrile did not change the result. The addition of hexamethylphosphoramide 
(HMPA) (entries 2, 15, 11, 13) or heating (entries 10–13) was not able to initiate the desired reaction as well. 
Upon work up, the cyclopentenones 24b–c were recovered. This inactivity could be explained by the lack of an 
electron-donating alkoxy group at C3 of 24b–c. In the case of 24b, the methyl group at C-4 proximal to the 
approaching Michael acceptor likely prevented its reaction due to steric hindrance (entries 9–11). 
 
 Scheme 3. Sequential Michael Reaction Reported by Yamada(28) 
 
Table 3. Attempted Double Michael Addition 
 
entry enone Michael acceptorb conditionsa additive resultc 
1 24c R1 = 4-FPh, R2 = CO2Me A none NR 
2 24c R1 = 4-FPh, R2 = CO2Me A HMPA (1 equiv) NR 
3 24c R1 = 4-FPh, R2 = CO2Me A none NR 
4 24c R1 = CF3, R2 = CO2Me A none NR 
5 24c R1 = CF3, R2 = CO2Me A HMPA (1 equiv) NR 
6 24c R1 = CF3, R2 = CO2Me A none NR 
7 24c acrolein A none NR 
8 24c none, quenched with D2O A none deut.d 
9 24c R1 = H, R2 = CO2Et A none NR 
10 24c R1 = 4-FPh, R2 = CO2Me B none NR 
11 24c R1 = 4-FPh, R2 = CO2Me B HMPA (1 equiv) NR 
12 24c R1 = CF3, R2 = CO2Me B none NR 
13 24c R1 = CF3, R2 = CO2Me B HMPA (1 equiv) NR 
14 24b R1 = H, R2 = CO2Et A none NR 
15 24b acrylonitrile A none NR 
16 24b R1 = 4-FPh, R2 = CO2Me A none NR 
a Condition A: enones were deprotonated at −78 °C, followed by the addition of the Michael acceptor. All 
experiments except for entry 8 were kept at −78 °C for 2 h, then warmed up to rt and stirred for 22 h. Entry 8 
was quenched at −78 °C after LDA deprotonation; condition B: enones were deprotonated at −78 °C, followed by 
the addition of the Michael acceptor, then warmed up to rt and refluxed for 3 h. 
b 2 equiv of Michael acceptor were used in entries 1–13, each, and 1.2 equiv in entries 14–16. 
c NR = no reaction. 
d deut. = deuteration of α-carbon confirmed by 1H NMR. 
 
Hydrocyanation 
We reasoned that the use of a bicyclic[2.2.1]ketone substrate could be advantageous, because it could permit 
the ready generation of varied aryl-containing analogs (e.g., 32) via arylmetal 1,2-addition reactions, followed by 
the conversion of the resulting alcohols to nitriles via intermediate carbocations (9, Figure 3). However, one 
disadvantage of the tertiary alcohol to nitrile conversion is that it may only be high yielding for electron-rich 
arenes able to facilitate the SN1-type transformation. Cyanation of a p-methoxylphenyl-stabilized tertiary cation 
has been reported with monocyclic substrates,(29−31) and there are also examples of trapping tertiary 2-
norbornyl cations with nucleophiles,(32) without the extensive Wagner–Meerwein rearrangements of these 
nonclassical carbocations. We reasoned that an aryl substituent at the 2-position of the norbornane could 
inhibit rearrangements and permit trapping of the carbocation intermediate by a cyanide nucleophile at the 2-
position. We examined this strategy using model systems formed by treating camphor with 4-methoxyphenyl 
magnesium bromide to generate alcohol 32, followed by acidic dehydration to generate 33. These were 
separately reacted with two different acids and TMSCN (Scheme 4). Upon treatment with BF3–OEt2 and 
TMSCN, 32 quickly dehydrated and rearranged to give an inseparable mixture of dehydration product 33 and 
three other inseparable alkene products with GC–MS and NMR analysis consistent with Wagner–Meerwein and 
Nametkin rearrangements. The desired cyanation product 37 was not observed. Trapping of 2-norbornyl cation 
generated from 33 using TfOH and TMSCN(30)was also unsuccessful at a higher temperature (20 °C). 
 
 
Scheme 4. Attempted Cyanation of Camphor-Derived Alcohol 32 and Alkene 33 
 
SNAr and SN2 Substitutions 
An endo-selective SNAr reaction with 2-cyano-5-norbornene and aryl fluoride reported by Caron(33) suggested a 
promising path to desirable α-arylated nitriles (Scheme 5). In this approach, nitriles can be deprotonated with 
KHMDS and reacted with both electron-rich and electron-poor aryl fluorides, with 39 reported as a single (endo), 
presumably thermodynamic, diastereomer. We chose nitrile 40 to examine this approach for our application 
(Table4). Under Caron’s optimal conditions, 40 did not undergo the SNAr substitution with 1,2-difluorobenzene 
(entry 1). When forcing conditions were applied (1,2-difluorobenzene as the solvent, 115 °C), only a trace 
amount of 41a was observed via liquid chromatography–mass spectrometry (LC–MS), and most of 40 was 
decomposed, as followed by thin layer chromatography (TLC) (entry 2). We hypothesize that the substituted 
bridgehead next to the reaction center obstructed the approach of the arene electrophile. However, alkylation 
reactions were successful using iodomethane and benzyl bromide as electrophiles with quantitative conversion 
(entries 4 and 5). Single diastereomeric products were also characterized, which we presume are the endo 
products generated from the attack at the less hindered face of the nitrile anion, in accordance with Caron’s 
report.(33) 
 
 
Scheme 5. SNAr Reported by Caron(30) Using 2-Cyano-5-norbornene 
 
Table 4. Arylation/alkylation of Secondary Nitrile 40 
 
entrya electrophile solvent conditions results 
1 1,2-difluorobenzene (4 equiv) THF 75 °C, 12 h NRb 
2 1,2-difluorobenzene (excess) neat 90–115 °C, 24 h trace 41ab 
3 1,2-difluorobenzene (50 equiv) toluene 18-crown-6 (1 equiv), 100 °C 12 h NRb 
4 MeI (45 equiv) toluene 55 °C, 12 h quant. 41bc 
5 BnBr (5.5 equiv) toluene 55 °C, 12 h quant. 41cc 
a To a solution of 40 (2 mg, 0.01 M) was added the indicated amount of electrophile followed by KHMDS. 
b Observed by LC–MS. 
c Estimated NMR yield using pentachloroethane as an internal standard. NR = no reaction. 
 
Synthesis of Azasordarin Analogs 
We thus commenced our second-generation synthesis from the key intermediate 15,(21) we reported previously 
(Scheme 6). First, the bridgehead primary alcohol of 15 was oxidized to the carboxylic acid and protected using 
PMBCl to provide ester 42. In previous studies, deprotonation of the carbon α to the ketone in a compound 
similar to 42 caused ring opening through a retro-Michael pathway. In part to avoid this complication, 42 was 
subjected to a Wittig reaction to give olefin 43. Normal Wittig conditions resulted in a very sluggish reaction, 
presumably due to steric hindrance from the TBDPS ether; however, generation and reaction of the required 
ylide at high temperature (90 °C) yielded alkene 43 in nearly quantitative yield. The nitrile α-carbon of 43 was 
deprotonated by KHMDS and alkylated with three different alkyl halides to give exclusively the 
desired endo nitrile products, thus eliminating a significant weakness of our first-generation synthesis which had 
to rely on chromatographic separation of endo/exo diastereomers. The resulting compounds 44a–c were 
treated with TBAF to give primary alcohols 45a–c. Stereochemistry was confirmed at this stage, with nOe 
observed between R1and its two neighboring protons, as shown in Scheme 6. Protons were first assigned using a 
COSY experiment, then nOe signals were measured between H-10 and H-7 of 45a–c, as depicted in 
the Supporting Information. In the case of 45a, nOe between the exo-methyl protons and 5-Hexo was also 
observed. 
 
 
Scheme 6. Synthesis of Azasordarin Analogs 
 
45a–c were then activated with PhNTf2 to give triflates 46a–c. The glycones 47 and 48 were prepared using 
modifications of a reported protocol;(34)though 48 has not previously been used in sordarin analogs, its ease 
of synthesis and similarity to other N-PMB morpholine-based glycones(7)inspired us to try it. 
Glycosidation(35) of triflates 46 with glycones 47 and 48proceeded smoothly, and to our surprise, the PMB 
ester was also cleaved during these transformations to give the desired bridgehead carboxylic acids 49 and 50a–
c. These reactions proceeded in dimethylformamide (DMF) but did not work in tetrahydrofuran (THF). 50a–
c were obtained exclusively with what we assume to be the aglycones in the equatorial positions at the 
anomeric carbon. This is also consistent with the increased nucleophilicity of the β-anomer of 1-O-lithiated 
pyranoses in their reactions with alkyl triflates, leading to the highly selective formation of β-
glycosides.(36,37) The 1H NMR splitting of the anomeric proton of 47 in dry CDCl3 (4.94 (ddd, J = 9.0, 3.9, 2.2 
Hz)) is consistent with the hydroxyl group in the axial position due to the anomeric effect (the 9.0 Hz coupling is 
due to the splitting by OH). However, the diastereomeric anomeric protons in 50a (see expansion in NMR 
spectrum in the Supporting Information) have larger coupling constants of 4.9 and 5.5 Hz (versus 3.9 Hz 
of 47), which is more consistent with an equatorial disposition of the aglycone. Fuller and co-workers 
determined X-ray structures of triterpene natural product derivatives containing a morpholine-based glycone 
with an equatorial substitution at the anomeric position, with reported coupling constants of 4.1–6.8 
Hz.(38) Ultimately, an X-ray structure may be needed with related azasordarin analogs in the future to confirm 
this assignment. Since we generated racemic intermediates via this synthetic route, the final 
compounds 49 and 50a–c represent an approximate 1:1 mixture of racemic diastereomers, as observed by NMR. 
 
In Vitro Antifungal Testing 
The isomeric mixtures 49 and 50a–c were subjected to antifungal microdilution assays using Clinical and 
Laboratory Standards Institute methods M27-A3 and M38-A2 at the Fungus Testing Laboratory at the University 
of Texas Health Science Center at San Antonio. No inhibition of fungal growth was observed at up to 8 or 4 
μg/mL (50c), against C. albicans(isolate# CA1, CA2, CA3), Aspergillus fumigatus (isolate# AF1, AF2, AF3), Candida 
parapsilosis (CLSI QC), and Paecilomyces variotii (CLSI QC). Minimum inhibitory concentrations (MICs) were 
determined after 24 or 48 h (A. fumigatus), using fluconazole and voriconazole as positive controls. For 
comparison, sordarin itself has a reported MIC of 16 μg/mL vs wild type C. albicans (strain A28235),(39) and the 
azasordarin 3 was <0.008 μg/mL.(8) 
Conclusions 
After examining numerous strategies to stereoselectively furnish the key tertiary nitrile on the 
bicyclo[2.2.1]heptane core, we have established a second-generation synthesis that enables the incorporation of 
substituents at the C-2 position. The key step was the highly endo-selective alkylation of bicyclic nitrile 43, which 
was generated via the Diels–Alder reaction, as described in our previous report.(21) Additionally, our synthetic 
route facilitates the late stage incorporation of diverse glycones. Although the synthesized analogs 49 and 50a–
c failed to show activity as isomeric mixtures against several fungal species (at concentrations up to 8 μg/mL), 
this new synthetic route to azasordarin analogs will permit additional SAR studies not previously feasible. 
 
Experimental Section 
General Information 
Unless otherwise noted, all reagents and solvents, including anhydrous solvents, were purchased from 
commercial vendors and used as received. Reactions were performed in ventilated fume hoods with magnetic 
stirring and heated in oil baths, unless otherwise noted. Reactions were performed in air, unless otherwise 
noted. Chilled reactions (below −10 °C) were performed in an acetone bath in a vacuum dewar, using a Neslab 
CC 100 immersion cooler. Unless otherwise specified, reactions were not run under N2atmosphere. Deionized 
water was purified by charcoal filtration and used for reaction workups and in reactions with water. NMR 
spectra were recorded on Varian 300 or 400 MHz spectrometers as indicated. Proton and carbon chemical shifts 
are reported in parts per million (ppm; δ) relative to tetramethylsilane (1H δ 0), or CDCl3 (13C δ 77.16), (CD3)2CO 
(1H δ 2.05, 13C δ 29.84), DMSO-d6 (1H δ 2.50, 13C δ 39.5), or CD3OD (1H δ 3.31, 13C δ 49.00). NMR data are 
reported as follows: chemical shifts, multiplicity (obs = obscured, app = apparent, br = broad, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, comp = complex overlapping signals); coupling constant(s) in 
hertz; integration. Unless otherwise indicated, NMR data were collected at 25 °C. Filtration was performed by 
vacuum using VWR Grade 413 filter paper, unless otherwise noted. Analytical thin layer chromatography (TLC) 
was performed on Agela Technologies glass plates with 0.20 mm silica gel with F254 indicator. Visualization was 
accomplished with UV light (254 nm) and KMnO4 stain, unless otherwise noted. Flash chromatography was 
performed using Biotage SNAP cartridges filled with 40–60 μm silica gel on Biotage Isolera automated 
chromatography systems with photodiode array UV detectors. Unless otherwise mentioned, columns were 
loaded with crude compounds as DCM solutions. Tandem liquid chromatography/mass spectrometry (LC–MS) 
was performed on a Shimadzu LCMS-2020 with an autosampler, a photodiode array detector, and a single-
quadrupole MS with ESI and APCI dual ionization, using a Peak Scientific nitrogen generator. Unless otherwise 
noted, a standard LC–MS method was used to analyze reactions and reaction products: Phenomenex Gemini 
C18 column (100 × 4.6 mm2, 3 μm particle size, 110 A pore size); column temperature 40 °C; 5 μL of sample in 
MeOH or CH3CN at a nominal concentration of 1 mg/mL was injected, and peaks were eluted with a gradient of 
25–95% CH3CN/H2O (both with 0.1% formic acid) over 5 min, then 95% CH3CN/H2O for 2 min. Purity was 
measured by UV absorbance at 210 or 254 nm. Preparative liquid chromatography was performed on a 
Shimadzu LC-20AP preparative high-performance liquid chromatography (HPLC) with autosampler, dual 
wavelength detector, and fraction collector. Samples purified by preparative HPLC were loaded as dimethyl 
sulfoxide (DMSO) solutions. Chemical names were generated, and selected chemical properties were calculated 
using either ChemAxon Marvin suite or ChemDraw Professional 15.1. NMR data were processed using either 
MestreNova or ACD/NMR Processor Academic Edition software. High-resolution mass spectra (HRMS) were 
obtained at the University of Cincinnati Environmental Analysis Service Center (EASC) with an Agilent 6540 
Accurate-Mass with Q-TOF. Catalyst 25 was prepared according to a published protocol.(40) 
 
(7a-((tert-Butyldimethylsilyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(2,4-difluorophenyl)-
4,4a,5,7a-tetrahydrocyclopenta[b]pyran-6-yl)methyl acetate (20) 
To a solution of enal 18 (49.7 mg, 0.296 mmol) in DCM (2.7 mL) was added cyclopentadiene 14 (94.6 mg, 176 
μmol) in DCM (3 mL), and the mixture was stirred at rt for 24 h. TLC (10% EtOAc/hexanes) indicated complete 
consumption of the starting material, so the mixture was concentrated and purified on a 10 g SiO2 column (30% 
DCM/hexanes) to give 20 (64.2 mg, 52%) as a yellow oil. 1H NMR (300 MHz, acetone-d6) δ 7.76–7.60 (m, 4H), 
7.52–7.33 (m, 6H), 7.26 (td, J = 9.0, 6.6 Hz, 1H), 7.06–6.90 (m, 2H), 6.78 (d, J = 1.7 Hz, 1H), 5.93 (d, J = 1.8 Hz, 1H), 
4.77 (qt, J = 14.7, 1.4 Hz, 2H), 3.89 (dd, J = 10.7, 4.4 Hz, 1H), 3.80 (dd, J = 10.7, 4.7 Hz, 1H), 2.83 (s, 1H), 2.74–2.61 
(comp, 3H), 2.03 (s, 3H), 1.05 (s, 9H), 0.91 (s, 9H), 0.22 (s, 3H), 0.16 (s, 3H). 13C{1H} NMR (75 MHz, acetone-d6) δ 
170.7, 144.8, 144.0, 143.9, 136.5, 136.4, 134.2 (d, J = 9.8 Hz), 132.0, 130.9, 130.9, 130.8, 130.7, 128.9, 128.8, 
124.55 (t, J = 19.8 Hz), 112.16 (dd, J = 20.9, 3.6 Hz), 107.7, 105.06 (d, J = 25.9 Hz), 104.9, 64.1, 62.4, 50.3, 46.9, 
27.4, 26.2, 23.6, 20.8, 20.0, 18.5, −2.8. Decomposed to give 21under LC–MS conditions (formic acid/MeOH). 
 
(5-(((tert-Butyldiphenylsilyl)oxy)methyl)-4-(2-(2,4-difluorophenyl)-3-oxopropyl)-3-oxocyclopent-1-en-1-
yl)methyl acetate (21) 
To a solution of 20 (9.9 mg, 14 μmol) in MeOH (1 mL) in a 4 mL vial was added formic acid (50 μL, 1.2 mmol). 
After 5 min, TLC (10% EtOAc/hexanes) indicated the complete consumption of 21, so the reaction mixture was 
concentrated and purified by chromatography on a silica gel-packed pipette (10–20% EtOAc/hexanes) to give 
aldehyde 21 (1:1 diastereomeric mixture, 6.0 mg, 73%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 9.62 (d, J = 
1.4 Hz, 1H), 9.58 (t, J = 1.0 Hz, 1H), 7.66–7.49 (comp, 8H), 7.48–7.33 (comp, 12H), 7.25–7.15 (m, 1H), 7.02 (td, J = 
8.5, 6.2 Hz, 1H), 6.89–6.74 (comp, 4H), 6.11 (q, J = 1.7 Hz, 1H), 6.06 (q, J = 1.7 Hz, 1H), 5.01 (d, J = 17.2 Hz, 1H), 
4.92 (d, J = 17.4 Hz, 1H), 4.83–4.73 (m, 2H), 4.27 (dd, J = 9.4, 5.3 Hz, 1H), 3.95 (dd, J = 8.2, 5.6 Hz, 1H), 3.77 
(dd, J = 10.4, 4.0 Hz, 1H), 3.64 (dd, J = 10.5, 6.2 Hz, 1H), 3.59 (d, J = 5.0 Hz, 3H), 2.73–2.58 (m, 3H), 2.38 (ddd, J = 
13.9, 9.9, 5.3 Hz, 1H), 2.21–2.14 (m, 2H), 2.13 (s, 3H), 2.11 (s, 3H), 2.05–1.94 (m, 1H), 1.84 (ddd, J = 14.5, 9.4, 5.6 
Hz, 1H), 1.01 (s, 9H), 0.97 (d, J = 2.6 Hz, 9H). 13C{1H} NMR (75 MHz, CDCl3) δ 208.8, 208.5, 199.0, 198.5, 174.5, 
172.0 (dd, J = 263.0, 2.6 Hz), 135.7, 135.7, 135.6, 135.6, 132.9, 132.6, 132.6 (dd, J = 18.6, 6.2 Hz), 131.2, 131.1, 
130.2, 130.2, 130.2, 129.2 (d, J = 10.6 Hz), 128.0, 112.3 (dd, J = 21.3, 3.5 Hz), 112.1 (dd, J = 20.9, 4.0 Hz), 111.9, 
104.64 (t, J = 25.7 Hz), 64.0, 63.5, 62.8, 62.5, 51.2, 51.0, 50.2, 49.3, 46.2, 45.5, 30.4, 30.0, 29.9, 26.9, 26.8, 20.8, 
20.8, 19.3, 19.3. HRMS (ESI+): calcd for C34H36F2NaO5Si [M + Na]+ 613.2198; found 613.2207. 
Methyl 1-(Acetoxymethyl)-5-((tert-butyldimethylsilyl)oxy)-7-(((tert-butyldiphenylsilyl)oxy)methyl)-2-
(trifluoromethyl)bicyclo[2.2.1]hept-5-ene-2-carboxylate (23) 
To a solution of cyclopentadiene 14 (10 mg, 18.7 μmol) in DCM (0.4 mL) was added methyl 2-
(trifluoromethyl)acrylate (22) (4.6 μL, 37.4 μmol) in 1 mL of DCM, and the mixture was stirred at rt for 24 h. TLC 
indicated the complete consumption of the starting material (20% EtOAc/hexanes), so the mixture was 
concentrated and purified by chromatography on a Pasteur pipette packed with silica gel (4% EtOAc/hexanes) to 
give cycloadduct 23 (1:1.4 diastereomeric mixture, 5.2 mg, 40%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.67–7.55 (comp, 6H), 7.46–7.32 (comp, 8H), 4.56–4.02 (comp, 5H), 3.76 (s, 3H), 3.71 (s, 2H), 3.63 (dd, J = 10.2, 
5.0 Hz, 1H), 3.51 (dd, J = 10.1, 5.0 Hz, 1H), 2.92–2.76 (m, 3H), 2.59 (d, J = 13.0 Hz, 1H), 2.50 (ddd, J = 21.3, 9.2, 5.0 
Hz, 2H), 2.19 (dd, J = 12.9, 3.5 Hz, 1H), 1.91 (d, J = 12.5 Hz, 1H), 1.77 (d, J = 2.0 Hz, 6H), 1.03 (d, J = 4.3 Hz, 18H), 
0.93 (d, J = 3.1 Hz, 18H), 0.16 (d, J = 7.6 Hz, 5H), 0.12 (d, J = 13.8 Hz, 4H). 19F NMR (376 MHz, CDCl3) δ −61.52, 
−64.24. 13C{1H} NMR (75 MHz, CDCl3) δ 170.7, 170.3, 169.8, 169.0, 162.6, 162.3, 135.7, 135.6, 133.9, 133.8, 133.8, 
133.7, 129.7, 127.8, 99.6, 97.4, 62.9, 62.6, 61.8, 61.1, 60.5, 60.0, 59.5, 58.4, 52.9, 52.9, 47.4, 46.4, 34.6, 34.5, 
27.0, 25.7, 20.6, 19.4, 18.1, 0.2, −4.5, −4.6. HRMS (ESI+): calcd for C36H50F3O6Si2 [M + H] 691.3098; found 
691.3111. 
 
(1S,2S,4R)-2-(4-Methoxyphenyl)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol (32)(41) and (1S,4R)-2-(4-
methoxyphenyl)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ene (33)(42) 
To a solution of (R)-camphor (219 mg, 1.44 mmol) in THF (7 mL) was added anhydrous cerium(III) chloride (355 
mg, 1.44 mmol). The mixture was sealed under N2 and stirred for 0.5 h, then 0.5 M (4-
methoxyphenyl)magnesium bromide in THF (3.2 mL, 1.58 mmol) was added. The resulting yellow solution was 
stirred for 0.5 h at rt, then quenched with NH4Cl (5 mL). GC–MS indicated that the organic layer contained a 
mixture of 32, 33, and unreacted starting material. The organic layer was separated, and the aqueous layer was 
extracted with EtOAc (3 × 5 mL). The combined organics were dried over Na2SO4, filtered, concentrated, and 
purified by flash chromatography (25 g SiO2 column, 0–7% EtOAc/hexanes) to give 32 (131 mg, 35%) as a 
colorless solid. 1H NMR (300 MHz, CDCl3) δ 7.45 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 3.81 (s, 3H), 2.28 (d, J = 
13.8 Hz, 1H), 2.18 (ddd, J = 13.9, 4.2, 3.0 Hz, 1H), 1.89 (t, J = 4.3 Hz, 1H), 1.78 (s, 1H), 1.77–1.64 (m, 1H), 1.26 (s, 
3H), 1.24–1.11 (m, 2H), 0.92–0.90 (m, 3H), 0.90 (s, 3H), 0.89–0.78 (m, 1H). 33 was also obtained (41 mg, 12%) as 
a yellow solid. 1H NMR (CDCl3) δ 7.19 (d, J = 8.9 Hz, 2H), 6.85 (d, J = 8.9 Hz, 2H), 5.90 (d, J = 3.3 Hz, 1H), 3.80 (s, 
3H), 2.36 (t, J = 3.5 Hz, 1H), 1.93 (ddt, J = 11.6, 8.7, 3.7 Hz, 1H), 1.70–1.61 (m, 1H), 1.33–1.22 (m, 1H), 1.13–1.05 
(comp, 4H), 0.88 (s, 3H), 0.81 (s, 3H). 
 
7-(((tert-Butyldiphenylsilyl)oxy)methyl)-1-((methoxymethoxy)methyl)-5-
methylenebicyclo[2.2.1]heptane-2-carbonitrile (40) 
To a solution of 15 (110 mg, 0.254 mmol) in CHCl3 (5 mL) were added dimethoxymethane (224 μL, 2.54 mmol) 
and P2O5 (500 mg, 1.76 mmol).(43)The mixture was sealed under N2 and stirred for 10 min. TLC (20% 
EtOAc/hexanes) indicated complete consumption of the starting material, the mixture was filtered through 
Celite and concentrated, and the intermediate MOM ether was used directly in the next step. To a solution of 
methyltriphenylphosphonium bromide (272 mg, 0.762 mmol) in toluene (5 mL) sealed under N2 was added 
KHMDS (0.5 M in toluene, 1.52 mL, 0.762 mmol). The mixture was heated to 90 °C for 30 min, then the 
intermediate MOM ether was added (in toluene, 5 mL). The mixture was stirred at 90 °C for 10 min, after which 
time TLC (40% EtOAc/hexanes) indicated complete consumption of the starting material. The mixture was 
filtered through Celite, concentrated, and loaded as a toluene solution onto a 10 g SiO2 column and purified by 
chromatography (5–10% EtOAc/hexanes) to give alkene 40 (1:0.7 diastereomeric mixture, 75 mg, 62%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.73–7.58 (comp, 7H), 7.49–7.31 (comp, 10H), 4.98 (t, J = 2.5 Hz, 1H), 
4.93–4.87 (m, 1H), 4.80 (s, 1H), 4.71 (s, 1H), 4.65–4.57 (m, 1H), 4.57–4.49 (m, 2H), 3.90 (d, J = 10.1 Hz, 1H), 3.73 
(d, J = 10.1 Hz, 1H), 3.70–3.61 (m, 1H), 3.59–3.43 (comp, 4H), 3.35 (s, 2H), 3.24 (s, 3H), 3.09 (ddd, J = 12.0, 5.0, 
2.5 Hz, 1H), 2.85 (d, J = 4.3 Hz, 1H), 2.75 (q, J = 5.8, 5.2 Hz, 1H), 2.47 (dd, J = 17.1, 2.1 Hz, 1H), 2.28 (dd, J = 12.3, 
4.3 Hz, 1H), 2.23–1.96 (comp, 5H), 1.89 (dd, J = 12.6, 9.4 Hz, 1H), 1.69 (dd, J = 12.5, 5.0 Hz, 1H), 1.05 (s, 6H), 1.03 
(s, 9H). 13C{1H} NMR (75 MHz, CDCl3) δ 150.3, 149.5, 135.7, 135.7, 135.7, 135.6, 133.6, 133.5, 133.4, 133.2, 129.9, 
129.8, 127.9, 127.8, 127.8, 127.8, 121.5, 121.1, 107.1, 106.6, 96.9, 96.6, 69.4, 66.3, 61.1, 61.1, 55.5, 55.4, 53.1, 
52.9, 52.8, 47.6, 38.0, 35.4, 34.9, 34.5, 33.7, 32.4, 26.9, 19.3, 19.3. HRMS (ESI+): calcd for C29H37NNaO3Si [M + 
Na]+ 498.2440; found 498.2452. 
 
4-Methoxybenzyl-7-(((tert-butyldiphenylsilyl)oxy)methyl)-2-cyano-5-oxobicyclo[2.2.1]heptane-1-
carboxylate (42) 
CrO3 (525 mg, 5.25 mmol) was dissolved in H2O (2 mL). To the solution was added concentrated H2SO4 (0.45 mL), 
to give the Jones reagent (2.5 mL). To a solution of alcohol 15 (767 mg, 1.769 mmol) in acetone (20 mL) in a 50 
mL round-bottom flask at 0 °C was added Jones reagent (1.77 mL, 4.42 mmol), and the mixture was stirred for 
30 min at rt. TLC (40% EtOAc/hexanes) showed complete consumption of the starting material, so the mixture 
was quenched with MeOH (5 mL). Na2SO4 was added, and the mixture was filtered through Celite, and the 
mother liquor was condensed to a green residue. The crude was dissolved in DCM (10 mL) and passed through a 
10 g silica gel pad, eluting with 80% EtOAc/hexanes. The resulting eluent was concentrated to give a crude 
yellow oil, which was dissolved in acetone (20 mL) in a 50 mL flask. To this solution were added PMBCl (360 μL, 
2.65 mmol), K2CO3 (1.222 g, 8.84 mmol), and TBAI (13.1 mg, 0.0354 mmol). The mixture was stirred for 24 h at rt, 
after which time LC–MS indicated incomplete consumption of the starting material. Additional PMBCl (0.200 mL, 
1.47 mmol) was added, and the mixture was stirred for another 24 h, after which time LC–MS showed complete 
conversion to the desired product. The mixture was filtered through Celite, concentrated, and purified by 
chromatography on a 10 g SiO2 column (0–40% EtOAc/hexanes) to give ester 42 (388 mg, 39% over three steps) 
as a colorless oil (1:1 diastereomeric mixture). 1H NMR (300 MHz, CDCl3) δ 7.67–7.51 (comp, 8H), 7.48–7.31 
(comp, 12H), 7.19 (dd, J = 14.1, 8.7 Hz, 4H), 6.81 (dd, J = 8.7, 1.8 Hz, 4H), 5.18–4.92 (comp, 4H), 3.89 (dd, J = 11.3, 
4.5 Hz, 1H), 3.78 (s, 6H), 3.60 (t, J = 6.2 Hz, 2H), 3.55–3.46 (m, 1H), 3.04–2.83 (comp, 4H), 2.82–2.75 (m, 2H), 
2.69–2.59 (m, 2H), 2.46 (ddd, J = 13.7, 11.8, 4.9 Hz, 1H), 2.40–2.33 (m, 1H), 2.28 (dt, J = 13.8, 4.8 Hz, 1H), 2.16–
2.06 (m, 2H), 1.79 (dd, J = 13.6, 5.4 Hz, 1H), 1.00 (d, J = 4.6 Hz, 18H). 13C{1H} NMR (75 MHz, CDCl3) δ 209.8, 209.7, 
169.6, 169.4, 159.9, 135.7, 135.6, 132.6, 132.5, 130.5, 130.2, 130.1, 130.0, 128.8, 128.0, 127.9, 127.0, 127.0, 
119.9, 119.2, 114.2, 114.1, 67.7, 60.7, 60.5, 55.6, 55.4, 54.5, 52.4, 51.7, 51.3, 43.8, 39.7, 35.2, 33.9, 29.7, 29.0, 
26.8, 19.2. HRMS (ESI+): calcd for C34H37 NNaO5Si [M + Na]+ 590.2339; found 590.2352. 
 
4-Methoxybenzyl-7-(((tert-butyldiphenylsilyl)oxy)methyl)-2-cyano-5-methylenebicyclo[2.2.1]heptane-1-
carboxylate (43) 
To a solution of methyltriphenylphosphonium bromide (18.9 mg, 0.0528 mmol) in dry toluene (1 mL) sealed 
under N2 atmosphere was added KHMDS (0.5 M in toluene, 106 μL, 0.0528 mmol), and the mixture was heated 
at 90 °C for 30 min. To the reaction was added 42 (5.0 mg, 8.8 μmol) in toluene (0.5 mL), and the mixture was 
stirred for 10 min. at the same temperature. TLC (20% EtOAc/hexanes) indicated complete consumption of the 
starting material, so the mixture was filtered through Celite and concentrated, then purified by chromatography 
on a silica gel-packed pipette (5–10% EtOAc/hexanes) to give alkene 43 (4.7 mg, 94%) as a colorless oil (1:1 
diastereomeric mixture). 1H NMR (300 MHz, CDCl3) δ 7.68–7.53 (comp, 8H), 7.48–7.30 (comp, 12H), 7.17 (dd, J = 
11.9, 8.7 Hz, 4H), 6.87–6.74 (comp, 4H), 5.14–4.90 (m, 6H), 4.82 (s, 1H), 4.78 (s, 1H), 3.99 (dd, J = 10.2, 4.6 Hz, 
1H), 3.79 (d, J = 1.1 Hz, 6H), 3.66 (dd, J = 10.6, 6.2 Hz, 1H), 3.56–3.35 (m, 3H), 3.06 (d, J = 4.2 Hz, 1H), 2.87 (d, J = 
4.1 Hz, 1H), 2.83 (dd, J = 9.3, 5.1 Hz, 1H), 2.73 (s, 2H), 2.59 (dd, J = 10.3, 4.6 Hz, 1H), 2.47 (d, J = 17.1 Hz, 1H), 2.35 
(dd, J = 12.3, 4.2 Hz, 1H), 2.30–2.11 (m, 3H), 1.97 (dd, J = 12.6, 9.3 Hz, 1H), 1.69 (dd, J= 12.5, 5.0 Hz, 1H), 1.03 (s, 
18H). 13C{1H} NMR (75 MHz, CDCl3) δ 171.1, 171.0, 159.9, 148.3, 147.9, 135.8, 135.7, 133.6, 133.4, 130.4, 130.2, 
130.0, 129.9, 129.8, 127.9, 127.9, 127.8, 127.5, 127.5, 121.1, 120.6, 114.2, 114.1, 107.8, 67.3, 61.1, 60.9, 56.9, 
56.5, 56.5, 55.5, 53.0, 48.4, 47.5, 38.3, 36.0, 35.5, 34.8, 34.5, 33.5, 29.9, 27.0, 19.5, 19.4. HRMS (ESI+): calcd for 
C35H39NNaO4Si [M + Na]+588.2546; found 588.2564. 
 
4-Methoxybenzyl-2-cyano-7-(hydroxymethyl)-2-methyl-5-methylenebicyclo[2.2.1]heptane-1-
carboxylate (45a) 
To a solution of 43 (57.3 mg, 101 μmol) in toluene (1 mL), sealed under N2, was added iodomethane (63.0 μL, 
1.01 mmol), followed by KHMDS (0.5 M in toluene, 0.61 mL, 0.30 mmol). The mixture was stirred at rt for 3 h, 
after which time TLC (10% EtOAc/hexanes) indicated complete consumption of the starting material. The 
mixture was quenched with saturated aqueous NH4Cl (1 mL), the organic phase was separated, and the aqueous 
phase was extracted with EtOAc (3 × 1 mL). The combined organics were dried over Na2SO4, filtered, 
concentrated, and used directly in the next step. To a solution of this intermediate (44a) (49.0 mg, 84.5 μmol) in 
THF (1 mL) was added a solution of TBAF (1.00 M in THF, 127 μL, 0.127 mmol) at 0 °C, and the mixture was 
removed from the ice bath and stirred at rt for 2 h. LC–MS indicated that some of the desired PMB ester 
products had been hydrolyzed to the carboxylic acid. The mixture was concentrated, then 1 N aqueous HCl (2 
mL) was added, and the solution was extracted with EtOAc (3 × 2 mL). The combined organics were dried over 
Na2SO4, concentrated, and redissolved in acetone (3 mL). To the solution were added PMBCl (9.2 μL, 0.0676 
mmol), K2CO3 (14.0 mg, 0.101 mmol), and 5–10 crystals of TBAI, and the mixture was stirred for 24 h at rt. TLC 
(100% EtOAc) indicated that the carboxylic acid was consumed. The mixture was filtered through Celite and 
concentrated, then purified by chromatography on a silica gel-packed Pasteur pipette, (30–40% EtOAc/hexanes), 
to give 45a (15.9 mg, 55%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.7 
Hz, 2H), 5.26 (d, J = 11.9 Hz, 1H), 5.11 (d, J = 11.9 Hz, 1H), 5.01 (t, J = 2.6 Hz, 1H), 4.87 (t, J = 2.2 Hz, 1H), 3.81 (s, 
3H), 3.76–3.63 (m, 1H), 3.60–3.44 (m, 1H), 3.10 (d, J = 8.4 Hz, 1H), 2.98 (dq, J = 17.5, 2.0 Hz, 1H), 2.68–2.54 (m, 
2H), 2.32 (t, J = 6.4 Hz, 1H), 2.12–1.97 (m, 1H), 1.84 (dd, J = 12.4, 3.6 Hz, 1H), 1.25 (s, 3H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 172.5, 159.9, 147.1, 134.9, 130.5, 130.4, 129.7, 128.7, 127.8, 127.2, 123.4, 114.1, 114.1, 114.1, 114.0, 
107.9, 67.4, 60.3, 60.2, 55.4, 50.8, 47.5, 45.0, 41.5, 36.2, 24.5. HRMS (ESI+): calcd for C20H23NNaO4 [M + 
Na]+ 364.1525; found 364.1530. 
 
4-Methoxybenzyl-2-cyano-2-ethyl-7-(hydroxymethyl)-5-methylenebicyclo[2.2.1]heptane-1-carboxylate 
(45b) 
43 (20.0 mg, 33.7 μmol) was treated following the procedure of 45a using EtI instead of MeI. 45b was obtained 
in 4.6 mg, 38% yield. 1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.22 (d, J = 11.9 
Hz, 1H), 5.13 (d, J = 11.9 Hz, 1H), 5.02 (t, J = 2.6 Hz, 1H), 4.86 (t, J = 2.2 Hz, 1H), 3.81 (d, J = 0.5 Hz, 3H), 3.70 
(dd, J = 11.7, 7.4 Hz, 1H), 3.60–3.43 (m, 1H), 3.12–2.94 (m, 2H), 2.70–2.52 (m, 2H), 2.31 (t, J = 6.4 Hz, 1H), 1.97–
1.81 (m, 2H), 1.50–1.34 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ 172.7, 159.9, 147.2, 130.4, 
127.2, 122.2, 114.1, 107.9, 67.3, 60.7, 60.3, 55.4, 51.3, 47.8, 47.7, 41.8, 36.6, 29.3, 8.9. HRMS (ESI+): calcd for 
C21H25NNaO4 [M + Na]+ 378.1681; found 378.1687. 
 
4-Methoxybenzyl-2-benzyl-2-cyano-7-(hydroxymethyl)-5-methylenebicyclo[2.2.1]heptane-1-carboxylate 
(45c) 
43 (20.0 mg, 33.7 μmol) was treated following the procedure of 45a using BnBr instead of MeI. 45c was obtained 
in 12 mg, 85% yield. 1H NMR (400 MHz, CDCl3) δ 7.46–7.27 (comp, 5H), 7.23–7.13 (m, 2H), 6.96–6.82 (m, 2H), 
5.28 (d, J = 11.8 Hz, 1H), 5.11 (d, J = 11.8 Hz, 1H), 4.97 (t, J = 2.6 Hz, 1H), 4.84 (t, J = 2.1 Hz, 1H), 3.77 (d, J = 0.9 
Hz, 4H), 3.63–3.49 (m, 1H), 3.18 (s, 1H), 3.09 (d, J = 17.7 Hz, 1H), 2.75–2.55 (comp, 4H), 2.46 (t, J = 6.4 Hz, 1H), 
2.07 (dd, J= 13.1, 4.3 Hz, 1H), 1.56 (d, J = 13.1 Hz, 1H). 13C{1H} NMR (75 MHz, CDCl3) δ 172.5, 160.0, 147.0, 134.2, 
130.6, 130.5, 128.6, 127.7, 127.2, 122.7, 114.2, 107.9, 67.4, 61.0, 60.3, 55.4, 51.4, 47.7, 47.1, 41.2, 41.0, 36.5. 
HRMS (ESI+): calcd for C26H27NNaO4 [M + Na]+ 440.1838; found 440.1841. 
 
6-(2-Chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-ol (47) 
To a solution of (1-aminocyclopentyl)methanol(44) (3.10 g, 26.9 mmol) in EtOH (100 mL) was added 2,2-
dimethoxyacetaldehyde (60% in water, 4.47 mL, 29.6 mmol). The mixture was stirred at rt for 18 h, after which 
time crude NMR indicated complete conversion to the intermediate imine. The mixture was quenched with 50 
mL of 1 N aq. NaOH followed by 50 mL of H2O, then extracted with DCM (3 × 100 mL). The combined organics 
were dried over Na2SO4, filtered, concentrated, and redissolved in Et2O (100 mL) in a flask sealed under N2. 
LiAlH4 (1.02 g, 26.9 mmol) was added, and the mixture was stirred at rt for 30 min. The reaction was quenched 
by adding EtOAc (50 mL) and saturated aqueous Rochelle’s salt (100 mL). The organic phase was separated, and 
the aqueous phase was extracted with EtOAc (3 × 100 mL). The combined organics were washed with brine (100 
mL), dried over Na2SO4, filtered, and concentrated to give a colorless oil. The intermediate amine was dissolved 
in EtOH (60 mL), and 2,3-dichloroprop-1-ene (1.05 mL, 11.4 mol), NaHCO3 (2.00 g, 23.8 mol), and NaI (114 mg, 
0.763 mmol) were added. The mixture was heated to 80 °C under N2 atmosphere for 18 h, after which time 
crude NMR indicated about 10% conversion to the desired product. Additional NaI (1.14 g, 7.63 mmol), 
NaHCO3 (2.00 g, 23.8 mol), 5–10 crystals of TBAI and 2,3-dichloroprop-1-ene (0.1 mL, 1.09 mmol) were added. 
The mixture was refluxed at 87 °C under N2 atmosphere for 24 h, after which time crude NMR indicated about 
80% conversion. The mixture was heated to 100 °C for another 2 h, then filtered through Celite and 
concentrated to a yellow oil, which was dissolved in conc. HCl (60 mL). The mixture was then refluxed at 105 °C 
under N2 atmosphere for 2 h, the solvent was evaporated, and 6 N NaOH (30 mL) was added. The mixture was 
extracted with EtOAc (3 × 30 mL), and the combined organics were washed with brine and dried over Na2SO4, 
filtered, concentrated, and purified by chromatography (10–40% EtOAc/hexanes) to give 47 (390 mg, 22% 
overall yield) as a colorless solid. 1H NMR (400 MHz, CDCl3) δ 5.40 (app q, J = 1.2 Hz, 1H), 5.30 (app q, J = 1.0 Hz, 
1H), 4.94 (ddd, J= 9.0, 3.9, 2.2 Hz, 1H), 3.82 (d, J = 9.1 Hz, 1H), 3.69 (dd, J = 11.4, 1.2 Hz, 1H), 3.25 (dd, J = 11.4, 
0.7 Hz, 1H), 3.16 (dt, J = 15.0, 1.3 Hz, 1H), 2.96 (d, J = 14.8 Hz, 1H), 2.69 (dd, J = 11.6, 2.2 Hz, 1H), 2.46 (dd, J = 
11.6, 3.9 Hz, 1H), 1.86–1.30 (comp, 8H). 13C{1H} NMR (101 MHz, CDCl3) δ 140.2, 114.2, 91.5, 69.4, 66.0, 56.4, 
52.8, 31.7, 28.4, 25.9, 25.8. HRMS (ESI+): calcd for C11H19ClNO2 [M + H] 232.1104; found 232.1106. 
 
2-Hydroxy-4-(4-methoxybenzyl)morpholin-3-one (48)(34) 
A solution of 50 wt % aqueous glyoxylic acid (9.14 g, 99.3 mmol) in THF (20 mL) was heated to reflux, then 2-(4-
methoxybenzylamino)ethanol(45) (6.00 g, 33.1 mmol) was added over 30 min, and the reaction was refluxed 
for another 2 h. THF was distilled off under atmospheric pressure while maintaining a constant volume by 
simultaneous addition of water (20 mL). The mixture was cooled to rt, then placed in an ice bath for 30 min, 
where the product crystallized. The solids were filtered with a Buchner funnel, washed with water, and then 
dried under vacuum at 60 °C for 24 h to give 48 (3.6 g, 46%) as a colorless solid. 1H NMR (400 MHz, CDCl3) δ 7.20 
(d, J = 7.0 Hz, 2H), 6.86 (d, J= 7.0 Hz, 2H), 5.34 (s, 1H), 4.91 (s, 1H), 4.65 (d, J = 14.4 Hz, 1H), 4.44 (d, J = 14.4 Hz, 
1H), 4.30–4.18 (m, 1H), 3.80 (s, 3H), 3.78–3.74 (m, 1H), 3.42 (td, J = 11.2, 10.6, 3.9 Hz, 1H), 3.11 (d, J = 12.4 Hz, 
1H). 
 
2-Cyano-7-(((-4-(4-methoxybenzyl)-3-oxomorpholin-2-yl)oxy)methyl)-2-methyl-5-
methylenebicyclo[2.2.1]heptane-1-carboxylic acid (49) 
45a (6.0 mg, 17.6 μmol) was treated following the same procedure of 50ausing 48 instead of 47, 49 was 
obtained in 1.5 mg, 19% yield, as a diastereomeric mixture. 1H NMR (400 MHz, CD3OD) δ 7.18 (d, J = 8.1 Hz, 2H), 
6.87 (d, J = 8.1 Hz, 2H), 5.10–4.95 (m, 1H), 4.94–4.80 (m, 1H), 4.63 (t, J = 15.7 Hz, 1H), 4.37 (t, J = 16.0 Hz, 1H), 
4.24–3.89 (m, 2H), 3.72–3.60 (m, 1H), 3.42 (td, J = 12.4, 11.7, 4.8 Hz, 1H), 3.09 (d, J = 12.6 Hz, 1H), 2.93–2.75 (m, 
2H), 2.44 (d, J = 17.8 Hz, 1H), 2.31 (d, J = 9.9 Hz, 1H), 2.03–1.82 (m, 2H), 1.58 (s, 0H), 1.45 (s, 3H), 1.36–1.13 
(comp, 5H). 13C{1H} NMR (151 MHz, CD3OD) δ 174.1, 174.0, 166.3, 166.2, 160.9, 160.9, 150.0, 150.0, 130.7, 130.6, 
129.2, 124.8, 124.8, 115.2, 115.1, 108.4, 108.2, 97.9, 97.0, 91.7, 67.8, 67.6, 67.0, 60.8, 57.9, 57.9, 50.0, 49.7, 
46.6, 46.4, 46.1, 45.9, 42.6, 37.3, 33.1, 30.6, 30.5, 30.3, 30.2, 28.1, 26.9, 25.1, 25.0, 23.8. HRMS (ESI+): calcd for 
C24H28N2NaO6 [M + Na]+ 463.1845; found 463.1855, HPLC (Phenomenex Gemini C18) (25% (0–1.5 min)–95% (3.5–
10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT = 8.10 min. 
 
7-(((-6-(2-Chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-yl)oxy)methyl)-2-cyano-2-methyl-5-
methylenebicyclo[2.2.1]heptane-1-carboxylic acid (50a) 
To a solution of 45a (18.0 mg, 52.7 μmol) and PhNTf2 (20.7 mg, 58.0 μmol) in Et2O (1 mL), sealed under N2 and at 
−50 °C, was added KHMDS (0.5 M in toluene, 211 μL, 105 μmol), and the mixture was stirred at the same 
temperature for 10 min. TLC indicated complete consumption of the starting material (40% EtOAc/hexane). The 
mixture was quenched with aq. NH4Cl (1 mL) at the same temperature, then extracted with EtOAc (3 × 1 mL). 
The combined organics were dried over Na2SO4, filtered, and concentrated to give the crude triflate, which was 
used directly in the next step. To a solution of 47(6.1 mg, 26 μmol) in DMF (0.2 mL) was added NaH (60% in 
mineral oil, 3.4 mg, 88 μmol) at 0 °C. The mixture was stirred at rt for 15 min, then a solution of the crude triflate 
in DMF (0.1 mL) was added. The mixture was stirred at rt for 1 h, after which time LC–MS indicated complete 
consumption of the starting material. The reaction was quenched with saturated aqueous NH4Cl (3 mL) and 
extracted with EtOAc (3 × 3 mL). The combined organics were washed with brine, dried over Na2SO4, filtered, 
concentrated, and purified by preparative HPLC to give 50a (3.3 mg, 43%) as a colorless oil (1.0:1.1 
diastereomeric mixture). 1H NMR (300 MHz, CDCl3) δ 5.61–5.50 (m, 2H), 5.31 (d, J = 1.2 Hz, 2H), 5.11–5.02 (m, 
2H), 4.94 (s, 2H), 4.59 (dd, J = 4.9, 2.7 Hz, 1H), 4.54 (dd, J = 5.5, 2.7 Hz, 1H), 4.08 (dd, J = 9.7, 5.7 Hz, 1H), 3.68 
(d, J = 7.8 Hz, 2H), 3.59 (dd, J = 11.1, 3.8 Hz, 2H), 3.38–3.17 (m, 3H), 3.04 (d, J = 5.5 Hz, 5H), 2.97 (s, 1H), 2.84 
(d, J = 3.9 Hz, 1H), 2.79 (d, J = 4.0 Hz, 1H), 2.72–2.64 (comp, 3H), 2.60 (d, J = 2.7 Hz, 1H), 2.44 (ddd, J = 11.7, 9.3, 
5.1 Hz, 2H), 2.16–2.30 (comp, 12H, presumably obs w/H2O), 2.13 (dd, J = 12.6, 2.3 Hz, 2H), 1.89 (dt, J = 12.7, 3.8 
Hz, 2H), 1.59 (d, J = 10.5 Hz, 6H), 1.51 (d, J = 1.0 Hz, 6H). 13C{1H} NMR (151 MHz, CDCl3) δ 172.4, 172.4, 147.2, 
147.1, 140.1, 140.0, 123.4, 123.3, 113.3, 113.1, 108.6, 108.5, 98.7, 98.2, 70.8, 70.3, 68.1, 65.6, 65.5, 65.5, 65.3, 
59.5, 59.5, 57.0, 56.9, 52.1, 52.0, 48.2, 48.1, 47.7, 47.6, 44.9, 44.9, 41.9, 41.8, 41.0, 36.2, 36.2, 29.9, 29.8, 25.8, 
25.7, 25.0, 25.0, 22.9, 14.3. HRMS (ESI+): calcd for C23H32ClN2O4 [M + H] 435.2051; found 435.2060; HPLC 
(Phenomenex Gemini C18) (25% (0–1.5 min)–95% (3.5–10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT = 7.30 
min. 
 
7-(((-6-(2-Chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-yl)oxy)methyl)-2-cyano-2-ethyl-5-
methylenebicyclo[2.2.1]heptane-1-carboxylic acid (50b) 
Following the same procedure of 50a using 45b (5.6 mg, 16 μmol) instead of 45a, 50b was obtained (1.5 mg, 
20%) as a diastereomeric mixture (1.0:1.1). 1H NMR (400 MHz, CDCl3) δ 5.60–5.52 (m, 2H), 5.30 (s, 2H), 5.10–
5.05 (m, 2H), 4.94 (s, 2H), 4.61–4.56 (m, 1H), 4.54 (dd, J = 5.5, 2.7 Hz, 1H), 4.08 (dd, J = 9.7, 5.5 Hz, 1H), 3.81 
(d, J = 1.0 Hz, 1H), 3.68 (d, J = 7.0 Hz, 2H), 3.58 (dd, J = 11.0, 4.5 Hz, 2H), 3.32 (t, J = 9.2 Hz, 1H), 3.23 (dd, J = 16.4, 
11.1 Hz, 2H), 3.13–2.96 (comp, 6H), 2.86 (s, 1H), 2.80 (s, 1H), 2.71–2.56 (m, 2H), 2.49–2.35 (comp, 4H), 2.07–
1.97 (m, 1H), 1.95 (t, J = 3.1 Hz, 5H), 1.92–1.78 (m, 2H), 1.69–1.45 (comp, 16H, presumably obs w/H2O), 1.28 (s, 
1H), 1.15–1.04 (m, 6H). 13C{1H} NMR (151 MHz, CDCl3) δ 173.0, 147.2, 147.2, 140.1, 140.1, 133.8, 114.1, 113.3, 
113.1, 108.6, 108.5, 98.8, 98.1, 76.9, 70.8, 70.2, 65.7, 65.5, 65.5, 65.3, 57.0, 56.9, 52.1, 52.0, 48.6, 48.0, 47.8, 
47.8, 41.7, 41.6, 40.9, 37.1, 36.7, 36.7, 36.1, 32.1, 29.9, 29.8, 29.5, 29.5, 27.4, 25.8, 25.8, 25.8, 25.7, 22.9, 14.3. 
HRMS (ESI+): calcd for C24H34ClN2O4 [M + H] 449.2207; found 449.2225; HPLC (Phenomenex Gemini C18) (25% (0–
1.5 min)–95% (3.5–10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT = 7.06 min. 
 
2-Benzyl-7-(((-6-(2-chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-yl)oxy)methyl)-2-cyano-5-
methylenebicyclo[2.2.1]heptane-1-carboxylic acid (50c) 
Following the same procedure of 50a using 45c (7.8 mg, 19 μmol) instead of 45a, 50c was obtained (1.9 mg, 
21%) as a diastereomeric mixture (1:1.0). 1H NMR (400 MHz, CDCl3) δ 7.38–7.27 (comp, 10H), 5.57 (s, 1H), 5.53 
(s, 1H), 5.30 (s, 2H), 5.01 (d, J = 7.5 Hz, 2H), 4.89 (s, 2H), 4.64–4.58 (m, 1H), 4.57–4.50 (m, 1H), 4.25–4.08 (m, 1H), 
3.70 (dd, J = 20.1, 11.3 Hz, 2H), 3.59 (t, J = 10.7 Hz, 2H), 3.32 (t, J = 9.0 Hz, 1H), 3.26 (d, J = 11.1 Hz, 1H), 3.20 
(dd, J = 12.3, 6.3 Hz, 2H), 3.14–2.96 (comp, 6H), 2.84 (s, 1H), 2.77 (s, 1H), 2.72 (d, J = 12.0 Hz, 1H), 2.69–2.63 (m, 
2H), 2.62 (d, J = 0.7 Hz, 1H), 2.45 (ddd, J = 16.5, 12.8, 7.4 Hz, 5H), 2.14–2.02 (m, 2H), 1.57 (comp, 20H, 
presumably obs w/H2O). HRMS (ESI+): calcd for C29H35ClN2O4 [M + H] 511.2364; found 511.2370; HPLC 
(Phenomenex Gemini C18) (25% (0–1.5 min)–95% (3.5–10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT = 8.27 
min. 
 
General Procedure for Diels–Alder Reaction Using 22 (Table1) 
A solution of the indicated amount of Lewis acid and methyl 2-(trifluoromethyl)acrylate (2.3 μL, 18.7 μmol) in 
the indicated solvent (0.5 mL) was sealed under N2 and cooled to −78 °C. 14 (5.0 mg, 9.4 μmol) in the indicated 
solvent (0.2 mL) was then added by syringe, and the mixture was stirred and gradually warmed up to −30 °C over 
1 h. In an aluminum foil-wrapped Dewar flask, the mixture was stirred for 24 h at rt. The mixture was filtered 
through a poly(tetrafluoroethylene) syringe filter, concentrated, and dissolved in 0.6 mL of CDCl3 containing 
pentachloroethane (1.1 μL, 9.4 μmol). 1H and 19F NMR analysis was then conducted. 
 
Representative Procedure for Organocatalytic Diels–Alder Reaction Using Cyclopentanones 
(Table2) 
To a solution of 25(40) in toluene (0.2 M, 0.36 mL) and propionic acid (5.4 μL, 0.07 mmol) was added cyclopent-
2-en-1-one (20 μL, 0.24 mmol). (E)-4-Phenylbut-3-en-2-one (17.5 mg, 0.12 mmol) was added, and the mixture 
was sealed under N2 and heated to 60 °C The experiments were monitored by GC–MS after 24 h. 
 
General Procedure for Double Michael Addition (Table3) 
24a or 24b (14.0 μmol) was sealed under N2, dissolved in THF (0.5 mL), and cooled to 0 °C. LDA (1.37 M in 
heptane, 10.2 μL, 14.0 μmol) was added, and HMPA (2.4 μL, 14 μmol) was optionally added. The mixture was 
cooled to −78 °C, and the indicated amount of Michael acceptor in THF (0.5 mL) was added by syringe. The 
mixture was stirred for 2 h, then warmed up to rt and stirred for another 22 h. The reaction was quenched with 
saturated NH4Cl solution (1 mL) and extracted with EtOAc (3 × 1 mL). The combined organics were dried over 
Na2SO4, filtered, and concentrated prior to 1H NMR and LC–MS analyses. 
 
Attempted Cyanation of Camphor-Derived Alcohol 32 and Alkene 33 (Scheme 4) 
To a solution of 32 (17.4 mg, 66.8 μmol) in DCM (0.7 mL) sealed under N2 and cooled to −78 °C was added 
TMSCN (10.6 μL, 84.9 μmol), followed by the addition of boron trifluoride etherate (8.8 μL, 72 μmol), which 
caused the colorless solution to turn yellow. The mixture was stirred at −78 °C for 15 min, then warmed to rt. 
The reaction was stirred for another 15 min, then it was quenched with sat. aq. NaHCO3 (1 mL). The organic 
phase was separated, and the aqueous phase was extracted with DCM (3 × 1 mL). The combined organics were 
dried over Na2SO4, filtered, and concentrated prior to GC–MS and 1H NMR analyses. 
 
Alternatively, PhCF3 (0.5 mL) was sealed under N2, cooled to −20 °C, and TfOH (18.8 μL, 0.21 mmol) and TMSCN 
(25.8 μL, 0.21 mmol) were added. After 5 min, 33 (10 mg, 0.04 mmol) in PhCF3 (0.5 mL) was added dropwise at 
the same temperature. The mixture was allowed to warm to rt and stirred for 0.5 h. The reaction was quenched 
with aqueous NaOH (1 M, 1 mL), extracted with ethyl acetate (3 × 1 mL), dried over Na2SO4, filtered, and 
concentrated prior to GC–MS and 1H NMR analyses. 
 
General Procedure for Aryl/Alkylation of Secondary Nitrile 40 (Table4) 
To a solution of 40 (2.5 mg, 5.3 μmol) in the indicated solvent (0.5 mL) sealed under N2 was added the indicated 
amount of electrophile. KHMDS (0.5 M in toluene, 52.6 μL, 0.026 mmol) was then added. The mixture was 
heated at the indicated temperature for the indicated time. The reaction was worked up by washing with 1 N 
HCl (0.5 mL) and extracting with EtOAc (3 × 0.5 mL). The combined organics were dried over Na2SO4, filtered, and 
concentrated to give a crude product which was dissolved in CDCl3 containing pentachloroethane (5.26 μmol), 
prior to 1H NMR analysis. 
Supporting Information 
Synthesis of Simplified Azasordarin Analogs as Potential Antifungal Agents 
1H, 13C, COSY, and NOESY NMR spectra 
 
  
 
  
  
  
  
  
  
 
 
 
 
  
  
  
  
 
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  
   
LC-MS traces of 49 and 50a–c 
Shimadzu Open Solution 
Project: Dockendorff Lab 
Experiment: 6242wuy_20180803_05  
Experiment Description: Wizard-generated sample plate  
Sample: WYB-SDR-363-4-3 
Sample Description: WYB-SDR-363-4-3 
Data File Name: C:\Data\docken\yibiao\WYB-SDR-363-4-3.lcd 
Sample Location: Plate Number: 1 - Position: 79 
Run By: 6242wuy 
Run Started: Friday, August 3, 2018 7:09:16 PM 
Run Finished: Friday, August 3, 2018 7:19:15 PM 
Method: 051817_Std_Gemini_25_MeCN 
 
MS Chromatogram 
Group#1 Scan(+) EI : TIC 
 
 
MS Spectrum 
Group#1 - PDA Peak: 12, RT: 4.73 to 5.12 min 
 
 
PDA Chromatogram 
1: Wavelength 254 nm, Band Width 4 nm 
 
 
PDA Spectrum 
Peak: 12, RT: 4.89 min, 190 to 800 nm 
 
 
Sample: WYB-SDR-363-4-3  
Run By: 6242wuy  
Run Finished: Friday, August 3, 2018 7:19:15 PM 
 
MS Peak Table 
ID RT Scan Group Purity Purity Source Area % 
1 1.07 1: TIC 0.0  5.7 
2 3.37 1: TIC 3.4 PDA 3.34 min 9.6 
3 4.08 1: TIC 3.4 PDA 4.66 min 5.0 
4 4.97 1: TIC 22.1 PDA 4.89 min 78.1 
5 1.07 2: TIC 0.0  3.3 
6 3.39 2: TIC 3.4 PDA 3.34 min 3.2 
7 4.95 2: TIC 22.1 PDA 4.89 min 82.1 
8 5.69 2: TIC 6.6 PDA 5.78 min 10.3 
 
PDA Peak Table 
ID RT Multi-Chro  Table Index Area % 
9 1.54 1 5.1 
10 3.34 1 3.4 
11 4.66 1 3.4 
12 4.89 1 22.1 
13 5.78 1 6.6 
14 5.93 1 2.0 
15 6.19 1 3.2 
16 6.67 1 11.5 
17 7.09 1 12.2 
18 7.35 1 6.6 
19 7.49 1 4.4 
20 7.74 1 4.7 
21 7.87 1 3.8 
22 8.14 1 3.6 
23 8.29 1 2.1 
24 8.56 1 2.3 
25 1.01 2 4.8 
26 1.35 2 3.3 
27 1.49 2 2.6 
28 1.90 2 3.1 
29 2.10 2 4.1 
30 3.05 2 13.7 
31 3.17 2 3.0 
32 3.34 2 8.0 
33 3.71 2 3.9 
34 4.01 2 16.7 
35 4.89 2 16.1 
36 5.71 2 9.5 
37 1.01 3 5.9 
38 1.35 3 3.7 
39 1.49 3 2.9 
40 1.92 3 4.4 
41 2.12 3 3.9 
42 2.87 3 17.8 
43 3.33 3 11.2 
44 4.00 3 10.5 
45 4.89 3 29.7 
46 1.49 4 8.7 
47 7.47 4 9.6 
48 7.87 4 8.5 
49 8.28 4 7.1 
 
Shimadzu Open Solution 
Project: Dockendorff Lab 
Experiment: 6242wuy_20180906_02 
Experiment Description: Wizard-generated sample plate 
Sample: WYB-SDR-367-E8 
Sample Description: WYB-SDR-367-E8 
Data File Name: C:\Data\docken\yibiao\WYB-SDR-367-E8.lcd 
Sample Location: Plate Number: 1 - Position: 94 
Run By: 6242wuy 
Run Started: Thursday, September 6, 2018 2:44:11 AM 
Run Finished: Thursday, September 6, 2018 3:07:58 AM 
Method: 051817_Std_Gemini_25_MeCN 
 
MS Chromatogram 
Group#1 Scan(+) EI : TIC 
 
 
MS Spectrum 
Group#1 - PDA Peak: 38, RT: 4.22 to 5.42 min 
 
 
PDA Chromatogram 
3: Wavelength 200 nm, Band Width 4 nm 
 
 
PDA Spectrum 
Peak: 38, RT: 4.43 min, 190 to 800 nm 
 
 
 
 
Sample: WYB-SDR-367-E8 
Run By: 6242wuy  
Run Finished: Thursday, September 6, 2018 3:07:58 AM 
 
MS Peak Table 
ID RT Scan Group Purity Purity Source Area % 
1 3.17 1: TIC 0.0  6.4 
2 4.49 1: TIC 0.0  73.8 
3 4.86 1: TIC 2.0 PDA 5.14 min 7.2 
4 5.08 1: TIC 2.0 PDA 5.14 min 6.0 
5 5.65 1: TIC 3.1 PDA 5.60 min 6.6 
6 4.47 2: TIC 0.0  85.5 
7 5.53 2: TIC 3.1 PDA 5.60 min 9.7 
8 6.21 2: TIC 8.6 PDA 6.49 min 2.1 
 
PDA Peak Table 
 
ID RT Multi-Chro  Table Index Area % 
9 0.44 1 9.6 
10 0.94 1 4.1 
11 1.42 1 5.4 
12 1.70 1 3.2 
13 5.14 1 2.0 
14 5.60 1 3.1 
15 5.99 1 4.5 
16 6.49 1 8.6 
17 7.10 1 20.0 
18 7.36 1 6.6 
19 7.50 1 5.5 
20 7.77 1 4.7 
21 7.91 1 4.3 
22 8.21 1 3.8 
23 8.31 1 3.1 
24 1.01 2 9.0 
25 1.37 2 5.2 
26 1.99 2 8.7 
27 3.27 2 18.2 
28 3.58 2 11.8 
29 4.13 2 3.4 
30 4.43 2 17.5 
31 5.49 2 6.3 
32 5.96 2 5.6 
33 7.12 2 3.1 
34 1.00 3 9.6 
35 1.37 3 5.9 
36 1.99 3 11.7 
37 2.75 3 36.1 
38 4.43 3 18.5 
39 5.48 3 5.1 
40 5.96 3 5.0 
41 7.12 4 20.0 
42 7.51 4 22.2 
43 8.33 4 16.1 
 
Shimadzu Open Solution 
Project: Dockendorff Lab 
Experiment: 6242wuy_20181006_01 
Experiment Description: Wizard-generated sample plate 
Sample: WYB-SDR-369-2-1-HPLC 
Sample Description: WYB-SDR-369-2-1-HPLC 
Data File Name: C:\Data\docken\yibiao\WYB-SDR-369-2-1-HPLC.lcd 
Sample Location: Plate Number: 1 - Position: 95 
Run By: 6242wuy 
Run Started: Saturday, October 6, 2018 5:25:46 PM 
Run Finished: Saturday, October 6, 2018 5:55:50 PM 
Method: 051817_Std_Gemini_25_MeCN 
 
MS Chromatogram 
Group#1 Scan(+) EI : TIC 
 
 
MS Spectrum 
Group#1 - PDA Peak: 24, RT: 4.96 to 5.32 min 
 
 
PDA Chromatogram 
3: Wavelength 200 nm, Band Width 4 nm 
 
 
PDA Spectrum 
Peak: 24, RT: 5.14 min, 190 to 800 nm 
 
 
 
 
Sample: WYB-SDR-369-2-1-HPLC  
Run By: 6242wuy  
Run Finished: Saturday, October 6, 2018 5:55:50 PM 
 
MS Peak Table 
ID RT Scan Group Purity Purity Source Area % 
1 1.35 1: TIC 15.1 PDA 1.41 min 4.2 
2 3.11 1: TIC 3.5 PDA 3.16 min 5.1 
3 3.80 1: TIC 0.0  2.8 
4 5.16 1: TIC 38.9 PDA 5.14 min 86.7 
5 5.18 2: TIC 38.9 PDA 5.14 min 95.6 
 
PDA Peak Table 
ID RT Multi-Chro  Table Index Area % 
6 0.56 1 20.5 
7 1.11 1 5.3 
8 1.41 1 15.1 
9 2.81 1 7.6 
10 3.16 1 3.5 
11 4.72 1 5.8 
12 5.14 1 38.9 
13 1.06 2 17.0 
14 1.37 2 9.1 
15 1.95 2 13.4 
16 2.23 2 9.5 
17 2.62 2 43.6 
18 5.14 2 5.5 
19 1.07 3 15.8 
20 1.36 3 8.8 
21 1.96 3 13.0 
22 2.23 3 9.3 
23 2.61 3 39.1 
24 5.14 3 12.0 
25 1.27 4 5.9 
26 1.37 4 13.8 
27 2.23 4 2.5 
28 4.73 4 3.9 
 
Shimadzu Open Solution 
Project: Dockendorff Lab 
Experiment: 6242wuy_20180924_01 
Experiment Description: Wizard-generated sample plate 
Sample: WYB-SDR-368-2-F4 
Sample Description: WYB-SDR-368-2-F4 
Data File Name: C:\Data\docken\yibiao\WYB-SDR-368-2-F4.lcd 
Sample Location: Plate Number: 1 - Position: 84 
Run By: 6242wuy 
Run Started: Monday, September 24, 2018 1:49:12 AM 
Run Finished: Monday, September 24, 2018 2:23:07 AM 
Method: 051817_Std_Gemini_25_MeCN 
 
MS Chromatogram 
Group#1 Scan(+) EI : TIC 
 
 
MS Spectrum 
Group#1 - PDA Peak: 41, RT: 5.48 to 6.86 min 
 
 
PDA Chromatogram 
3: Wavelength 200 nm, Band Width 4 nm 
 
PDA Spectrum 
Peak: 41, RT: 5.65 min, 190 to 800 nm 
 
 
 
 
Sample: WYB-SDR-368-2-F4  
Run By: 6242wuy  
Run Finished: Monday, September 24, 2018 2:23:07 AM 
 
MS Peak Table 
ID RT Scan Group Purity Purity Source Area % 
1 1.09 1: TIC 15.9 PDA 0.48 min 4.3 
2 3.25 1: TIC 0.0  6.0 
3 3.71 1: TIC 0.0  12.1 
4 5.39 1: TIC 16.1 PDA 5.65 min 5.7 
5 5.69 1: TIC 16.1 PDA 5.65 min 71.9 
6 3.69 2: TIC 0.0  13.3 
7 5.40 2: TIC 16.1 PDA 5.65 min 9.8 
8 5.70 2: TIC 16.1 PDA 5.65 min 68.5 
9 5.92 2: TIC 2.8 PDA 6.09 min 3.3 
10 6.13 2: TIC 9.1 PDA 6.61 min 5.1 
 
PDA Peak Table 
ID RT Multi-Chro  Table Index Area % 
11 0.48 1 15.9 
12 1.49 1 5.7 
13 1.79 1 4.3 
14 5.65 1 16.1 
15 5.86 1 2.2 
16 6.09 1 2.8 
17 6.61 1 9.1 
18 7.12 1 14.7 
19 7.51 1 10.3 
20 7.77 1 4.0 
21 7.91 1 3.6 
22 8.18 1 2.9 
23 8.33 1 2.5 
24 1.01 2 9.4 
25 1.46 2 6.1 
26 2.15 2 9.4 
27 3.22 2 15.1 
28 3.43 2 2.2 
29 3.63 2 8.6 
30 4.03 2 18.0 
31 5.35 2 3.4 
32 5.65 2 7.6 
33 6.08 2 4.0 
34 7.13 2 2.3 
35 1.01 3 11.1 
36 1.47 3 7.3 
37 2.15 3 11.5 
38 2.84 3 23.3 
39 3.63 3 22.3 
40 5.35 3 2.8 
41 5.65 3 15.8 
42 1.47 4 14.4 
43 7.14 4 12.1 
44 7.80 4 12.8 
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